News About: R&D


Kuhnil first reveals Phase III clinical trial for Omega-3 & Rosuvastatin combination drug

Kuhnil(CEO Young-Joong Kim) announced the Phase III clinical trial result for ‘Rosumega SC,’ a dyslipidemia combination drug, was published in the SCI-level international journal ‘Clinical Therapeutics’ on 6 December....

Foreign CROs hot in Korea, accounting for more than 30% of total CROs in Korea

In the Korean clinical study market, foreign CROs(contract research organization) are reportedly getting popular. According to the ‘Korea Clinical Trail Industry Statistics’ published by the Korea National Enterprise...

Korea follows only 71.4% of U.S. drug development technology

It was analyzed the Korea’s technological level of drug development was 71.4% of what the U.S. had and the technological gap was 4.1 years. The Ministry of Health and Welfare and the Korea Health Industry Development...

Standigm reveals novel drug discovering services using new AI technology

A novel drug discovering company based on artificial intelligence ‘Standigm(CEO Jin-Han Kim)’ announced the company selected as the next-generation pharmaceutical and biotechnology company at the ‘23th Bio-Europe,’ an...

Phase III clinical trials accounted for the most of total clinical trials in Korea

Since the number of approvals for clinical trial plan was rapidly increasing for the past several years, it is now common to hear ‘clinical trial’ around us. Thus, the Ministry of Food and Drug Safety(MFDS) analyzed ...

‘Serious’ polarization of R&D investment among innovative pharmaceutical companies

It was criticized polarization of R&D investments was getting intensified among innovative pharmaceutical companies certified to have excellent new drug development and overseas expansion capabilities. While there is...

225 pipelines of biologics being developed in Korea

There were reportedly 225 cases of clinical trials for biologics being developed in Korea. According to the Ministry of Food and Drug Safety(MFDS), there were ongoing clinical trials for total 225 products at the end...

Eased responsibilities for challenging research failures

In order to promote R&D, the government will ease responsibilities for failures, but tighten restrictions on repeated wrongful uses of R&D expenses. The Ministry of Trade, Industry and Energy(Minister Woon-Kyu Baek, ...

7 of 11 biosimilars approved in Korea were developed by Korean company

It was reported there were the total 11 biosimilar products approved in Korea, such as ‘Remsima 100mg,’ and 7 of them were developed by Korean pharmaceutical companies. According to the Ministry of Food and Drug Safe...

Will the Pangyo era come with R&D center for small & medium pharmas?

Korea Pharmaceutical Ind. Coop. Chairman Yong-Jun Cho visited the Gyeonggi Provincial Government in the afternoon of the 4th and exchanged various opinions about small and medium pharmaceutical companies’ future direc...

TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.